Cell Death Differ:Fra-2/AP-1下调Fam212b表达调节黑色素瘤细胞的转移

2020-11-27 xiaozeng MedSci原创

目前转移性黑色素瘤仍是具有挑战性的疾病之一,患者的临床结局较差。尽管有一部分转移性黑素瘤患者受益于新疗法,但转移的发生也与患者的不良预后息息相关。转移是一个多步骤过程,涉及癌细胞在远端器官的分离、迁移

目前转移性黑色素瘤仍是具有挑战性的疾病之一,患者的临床结局较差。尽管有一部分转移性黑素瘤患者受益于新疗法,但转移的发生也与患者的不良预后息息相关。转移是一个多步骤过程,涉及癌细胞在远端器官的分离、迁移、定植和生存。目前对影响癌细胞转移行为的相关信号通路的了解还不清楚。因此,了解黑色素瘤如何转移的分子机制显得尤为重要。

该研究显示,在黑色素瘤细胞中AP-1转录因子成员Fra-2的表达下调与侵袭性黑色素瘤表型相关。研究人员发现,在黑色素瘤细胞中敲低Fra-2的表达能够引起Snail-1、Twist-1/2和MMP-2表达水平升高,并促进细胞迁移和侵袭作用。而在黑色素瘤细胞系中敲低Fra-2的表达可导致肺转移和肝转移的增加。

小鼠黑素瘤细胞中敲低Fra-2增加了肺转移和肝转移

Fra-2敲低黑色素瘤细胞转移潜力的增加可能是由于细胞周期的加快和组织血管生成的增加所引起的。通过Fra-2敲低细胞系微阵列分析,研究人员鉴定了Fam212b蛋白为Fra-2的下游靶标。通过在Fra-2突变细胞中进一步敲低Fam212b,研究人员发现,Fra-2敲低所诱导的细胞迁移、侵袭和细胞周期转化相关表型得到了减轻。此外,过表达Fam212b能够增强β-catenin信号通路,而Fam212b的表达也与患者黑色素瘤的转移增加和临床预后不良相关。

Fam212b是一种新型的恶性黑色素瘤生物标志物

总而言之,该研究结果揭示了Fra-2/Fam212b通路是黑色素瘤转移的一个新通路,其或可作为黑色素瘤转移特性的一个潜在靶标。


原始出处:

Chen, GL., Li, R., Chen, XX. et al. Fra-2/AP-1 regulates melanoma cell metastasis by downregulating Fam212b. Cell Death Differ (13 November 2020).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680701, encodeId=957e1680e0132, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Jun 28 20:53:51 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966922, encodeId=3b3d1966922e9, content=<a href='/topic/show?id=408a103334eb' target=_blank style='color:#2F92EE;'>#黑色素瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103334, encryptionId=408a103334eb, topicName=黑色素瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Feb 14 04:53:51 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872077, encodeId=611618e20779e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 17 03:53:51 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962379, encodeId=8d4919623e9e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 25 03:53:51 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784233, encodeId=a4241e84233f5, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Mar 18 22:53:51 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531696, encodeId=37f9153169652, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559035, encodeId=39f6155903526, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565044, encodeId=00181565044a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902929, encodeId=2da0902929c1, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/dGRA8ko3T9y4gtX60QSR2op9UI1h8ce7X3Q9jdbZ4HibnZwibViaG0cUOfMN3VPo54lRibvcebZANcFdDBueO17kVA/132, createdBy=c23b2491403, createdName=在路上的小医生, createdTime=Fri Nov 27 20:00:29 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902896, encodeId=a63c9028961c, content=目前转移性黑色素瘤仍是具有挑战性的疾病之一,患者的临床结局较差, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Fri Nov 27 17:53:47 CST 2020, time=2020-11-27, status=1, ipAttribution=)]
    2021-06-28 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1680701, encodeId=957e1680e0132, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Jun 28 20:53:51 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966922, encodeId=3b3d1966922e9, content=<a href='/topic/show?id=408a103334eb' target=_blank style='color:#2F92EE;'>#黑色素瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103334, encryptionId=408a103334eb, topicName=黑色素瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Feb 14 04:53:51 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872077, encodeId=611618e20779e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 17 03:53:51 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962379, encodeId=8d4919623e9e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 25 03:53:51 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784233, encodeId=a4241e84233f5, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Mar 18 22:53:51 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531696, encodeId=37f9153169652, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559035, encodeId=39f6155903526, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565044, encodeId=00181565044a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902929, encodeId=2da0902929c1, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/dGRA8ko3T9y4gtX60QSR2op9UI1h8ce7X3Q9jdbZ4HibnZwibViaG0cUOfMN3VPo54lRibvcebZANcFdDBueO17kVA/132, createdBy=c23b2491403, createdName=在路上的小医生, createdTime=Fri Nov 27 20:00:29 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902896, encodeId=a63c9028961c, content=目前转移性黑色素瘤仍是具有挑战性的疾病之一,患者的临床结局较差, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Fri Nov 27 17:53:47 CST 2020, time=2020-11-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1680701, encodeId=957e1680e0132, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Jun 28 20:53:51 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966922, encodeId=3b3d1966922e9, content=<a href='/topic/show?id=408a103334eb' target=_blank style='color:#2F92EE;'>#黑色素瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103334, encryptionId=408a103334eb, topicName=黑色素瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Feb 14 04:53:51 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872077, encodeId=611618e20779e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 17 03:53:51 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962379, encodeId=8d4919623e9e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 25 03:53:51 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784233, encodeId=a4241e84233f5, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Mar 18 22:53:51 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531696, encodeId=37f9153169652, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559035, encodeId=39f6155903526, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565044, encodeId=00181565044a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902929, encodeId=2da0902929c1, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/dGRA8ko3T9y4gtX60QSR2op9UI1h8ce7X3Q9jdbZ4HibnZwibViaG0cUOfMN3VPo54lRibvcebZANcFdDBueO17kVA/132, createdBy=c23b2491403, createdName=在路上的小医生, createdTime=Fri Nov 27 20:00:29 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902896, encodeId=a63c9028961c, content=目前转移性黑色素瘤仍是具有挑战性的疾病之一,患者的临床结局较差, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Fri Nov 27 17:53:47 CST 2020, time=2020-11-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1680701, encodeId=957e1680e0132, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Jun 28 20:53:51 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966922, encodeId=3b3d1966922e9, content=<a href='/topic/show?id=408a103334eb' target=_blank style='color:#2F92EE;'>#黑色素瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103334, encryptionId=408a103334eb, topicName=黑色素瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Feb 14 04:53:51 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872077, encodeId=611618e20779e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 17 03:53:51 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962379, encodeId=8d4919623e9e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 25 03:53:51 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784233, encodeId=a4241e84233f5, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Mar 18 22:53:51 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531696, encodeId=37f9153169652, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559035, encodeId=39f6155903526, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565044, encodeId=00181565044a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902929, encodeId=2da0902929c1, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/dGRA8ko3T9y4gtX60QSR2op9UI1h8ce7X3Q9jdbZ4HibnZwibViaG0cUOfMN3VPo54lRibvcebZANcFdDBueO17kVA/132, createdBy=c23b2491403, createdName=在路上的小医生, createdTime=Fri Nov 27 20:00:29 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902896, encodeId=a63c9028961c, content=目前转移性黑色素瘤仍是具有挑战性的疾病之一,患者的临床结局较差, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Fri Nov 27 17:53:47 CST 2020, time=2020-11-27, status=1, ipAttribution=)]
    2021-04-25 维他命
  5. [GetPortalCommentsPageByObjectIdResponse(id=1680701, encodeId=957e1680e0132, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Jun 28 20:53:51 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966922, encodeId=3b3d1966922e9, content=<a href='/topic/show?id=408a103334eb' target=_blank style='color:#2F92EE;'>#黑色素瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103334, encryptionId=408a103334eb, topicName=黑色素瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Feb 14 04:53:51 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872077, encodeId=611618e20779e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 17 03:53:51 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962379, encodeId=8d4919623e9e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 25 03:53:51 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784233, encodeId=a4241e84233f5, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Mar 18 22:53:51 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531696, encodeId=37f9153169652, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559035, encodeId=39f6155903526, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565044, encodeId=00181565044a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902929, encodeId=2da0902929c1, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/dGRA8ko3T9y4gtX60QSR2op9UI1h8ce7X3Q9jdbZ4HibnZwibViaG0cUOfMN3VPo54lRibvcebZANcFdDBueO17kVA/132, createdBy=c23b2491403, createdName=在路上的小医生, createdTime=Fri Nov 27 20:00:29 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902896, encodeId=a63c9028961c, content=目前转移性黑色素瘤仍是具有挑战性的疾病之一,患者的临床结局较差, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Fri Nov 27 17:53:47 CST 2020, time=2020-11-27, status=1, ipAttribution=)]
    2021-03-18 isabellayj
  6. [GetPortalCommentsPageByObjectIdResponse(id=1680701, encodeId=957e1680e0132, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Jun 28 20:53:51 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966922, encodeId=3b3d1966922e9, content=<a href='/topic/show?id=408a103334eb' target=_blank style='color:#2F92EE;'>#黑色素瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103334, encryptionId=408a103334eb, topicName=黑色素瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Feb 14 04:53:51 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872077, encodeId=611618e20779e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 17 03:53:51 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962379, encodeId=8d4919623e9e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 25 03:53:51 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784233, encodeId=a4241e84233f5, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Mar 18 22:53:51 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531696, encodeId=37f9153169652, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559035, encodeId=39f6155903526, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565044, encodeId=00181565044a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902929, encodeId=2da0902929c1, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/dGRA8ko3T9y4gtX60QSR2op9UI1h8ce7X3Q9jdbZ4HibnZwibViaG0cUOfMN3VPo54lRibvcebZANcFdDBueO17kVA/132, createdBy=c23b2491403, createdName=在路上的小医生, createdTime=Fri Nov 27 20:00:29 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902896, encodeId=a63c9028961c, content=目前转移性黑色素瘤仍是具有挑战性的疾病之一,患者的临床结局较差, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Fri Nov 27 17:53:47 CST 2020, time=2020-11-27, status=1, ipAttribution=)]
    2020-11-28 cy0328
  7. [GetPortalCommentsPageByObjectIdResponse(id=1680701, encodeId=957e1680e0132, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Jun 28 20:53:51 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966922, encodeId=3b3d1966922e9, content=<a href='/topic/show?id=408a103334eb' target=_blank style='color:#2F92EE;'>#黑色素瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103334, encryptionId=408a103334eb, topicName=黑色素瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Feb 14 04:53:51 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872077, encodeId=611618e20779e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 17 03:53:51 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962379, encodeId=8d4919623e9e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 25 03:53:51 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784233, encodeId=a4241e84233f5, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Mar 18 22:53:51 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531696, encodeId=37f9153169652, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559035, encodeId=39f6155903526, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565044, encodeId=00181565044a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902929, encodeId=2da0902929c1, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/dGRA8ko3T9y4gtX60QSR2op9UI1h8ce7X3Q9jdbZ4HibnZwibViaG0cUOfMN3VPo54lRibvcebZANcFdDBueO17kVA/132, createdBy=c23b2491403, createdName=在路上的小医生, createdTime=Fri Nov 27 20:00:29 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902896, encodeId=a63c9028961c, content=目前转移性黑色素瘤仍是具有挑战性的疾病之一,患者的临床结局较差, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Fri Nov 27 17:53:47 CST 2020, time=2020-11-27, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1680701, encodeId=957e1680e0132, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Jun 28 20:53:51 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966922, encodeId=3b3d1966922e9, content=<a href='/topic/show?id=408a103334eb' target=_blank style='color:#2F92EE;'>#黑色素瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103334, encryptionId=408a103334eb, topicName=黑色素瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Feb 14 04:53:51 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872077, encodeId=611618e20779e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 17 03:53:51 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962379, encodeId=8d4919623e9e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 25 03:53:51 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784233, encodeId=a4241e84233f5, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Mar 18 22:53:51 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531696, encodeId=37f9153169652, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559035, encodeId=39f6155903526, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565044, encodeId=00181565044a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902929, encodeId=2da0902929c1, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/dGRA8ko3T9y4gtX60QSR2op9UI1h8ce7X3Q9jdbZ4HibnZwibViaG0cUOfMN3VPo54lRibvcebZANcFdDBueO17kVA/132, createdBy=c23b2491403, createdName=在路上的小医生, createdTime=Fri Nov 27 20:00:29 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902896, encodeId=a63c9028961c, content=目前转移性黑色素瘤仍是具有挑战性的疾病之一,患者的临床结局较差, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Fri Nov 27 17:53:47 CST 2020, time=2020-11-27, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1680701, encodeId=957e1680e0132, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Jun 28 20:53:51 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966922, encodeId=3b3d1966922e9, content=<a href='/topic/show?id=408a103334eb' target=_blank style='color:#2F92EE;'>#黑色素瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103334, encryptionId=408a103334eb, topicName=黑色素瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Feb 14 04:53:51 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872077, encodeId=611618e20779e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 17 03:53:51 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962379, encodeId=8d4919623e9e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 25 03:53:51 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784233, encodeId=a4241e84233f5, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Mar 18 22:53:51 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531696, encodeId=37f9153169652, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559035, encodeId=39f6155903526, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565044, encodeId=00181565044a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902929, encodeId=2da0902929c1, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/dGRA8ko3T9y4gtX60QSR2op9UI1h8ce7X3Q9jdbZ4HibnZwibViaG0cUOfMN3VPo54lRibvcebZANcFdDBueO17kVA/132, createdBy=c23b2491403, createdName=在路上的小医生, createdTime=Fri Nov 27 20:00:29 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902896, encodeId=a63c9028961c, content=目前转移性黑色素瘤仍是具有挑战性的疾病之一,患者的临床结局较差, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Fri Nov 27 17:53:47 CST 2020, time=2020-11-27, status=1, ipAttribution=)]
    2020-11-27 在路上的小医生

    真好

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1680701, encodeId=957e1680e0132, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Jun 28 20:53:51 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966922, encodeId=3b3d1966922e9, content=<a href='/topic/show?id=408a103334eb' target=_blank style='color:#2F92EE;'>#黑色素瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103334, encryptionId=408a103334eb, topicName=黑色素瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Feb 14 04:53:51 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872077, encodeId=611618e20779e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 17 03:53:51 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962379, encodeId=8d4919623e9e7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Apr 25 03:53:51 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784233, encodeId=a4241e84233f5, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Thu Mar 18 22:53:51 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531696, encodeId=37f9153169652, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559035, encodeId=39f6155903526, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565044, encodeId=00181565044a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Nov 28 15:53:51 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902929, encodeId=2da0902929c1, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/dGRA8ko3T9y4gtX60QSR2op9UI1h8ce7X3Q9jdbZ4HibnZwibViaG0cUOfMN3VPo54lRibvcebZANcFdDBueO17kVA/132, createdBy=c23b2491403, createdName=在路上的小医生, createdTime=Fri Nov 27 20:00:29 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902896, encodeId=a63c9028961c, content=目前转移性黑色素瘤仍是具有挑战性的疾病之一,患者的临床结局较差, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5008534db22c474a844fbd107ff83af2/d3e20fc133b542208ff15e7f2b575329.jpg, createdBy=c7015311102, createdName=Jessie Zhang, createdTime=Fri Nov 27 17:53:47 CST 2020, time=2020-11-27, status=1, ipAttribution=)]
    2020-11-27 Jessie Zhang

    目前转移性黑色素瘤仍是具有挑战性的疾病之一,患者的临床结局较差

    0

相关资讯

Nature:检测黑素细胞基因组,有望预测黑色素瘤风险

皮肤黑色素瘤是由黑色素细胞(皮肤中产生色素的细胞)引起的皮肤癌,光照是形成黑色素瘤的主要诱变因素。对黑色素瘤肿瘤组织的测序发现,体细胞突变与之密切相关,因此早期诊断意义重大。

JCO:CheckMate 066试验| 纳武单抗治疗晚期黑色素瘤的5年随访结果

CheckMate 066试验研究了纳武单抗单药疗法作为既往未治疗过的BRAF野生型晚期黑色素瘤的一线疗法的疗效和安全性。现对该试验随访5年的结果进行汇报。

人各有“痣”:痣出现这些变化,有恶变的可能!黑色素瘤不能小看

黑痣在每个人身上都会出现,如果有细心观察的话就会发现,很多人的脖子后面都长了一颗黑痣。部分人是出生之后就有,而有的人是后期长起来的。人脖子有黑痣,是好是坏?脖子后面有黑痣其实是个很正常的现象,不必太过

Eur J Cancer:鉴别高复发风险的I/IIA期黑色素瘤的新模型

辅助治疗可延长III期黑色素瘤患者的无复发存活期(RFS),以至于IIIA/B期黑色素瘤的5年黑色素瘤特异性存活率(MSS)可达到83-93%,与IIB/C期的患者的相近(82-87%)。目前,I/I

“模拟病毒的药物”可帮助免疫系统靶向狡猾的癌细胞

加州大学洛杉矶分校(UCLA)的研究人员发现,一种像病毒一样激活人体自然防御能力的药物可能使某些隐形的黑色素瘤细胞对免疫系统可见,从而可以通过免疫疗法更好地攻击这些癌细胞。

免疫联合疗法O药+Y药:黑色素瘤辅助治疗的III期临床失败

百时美施贵宝的免疫联合疗法(PD-1单抗Opdivo联合CTLA-4单抗Yervoy):在已完成手术切除的高危黑色素瘤患者中未达到实验终点。